These results suggest that EXO1 expression could complement BRCA1/2 genotyping as a functional biomarker for HRD, expanding therapeutic eligibility for PARP-inhibitor–based regimens beyond BRCA-mutated cases. This evidence concerns the gene EXO1 and hypoparathyroidism-retardation-dysmorphism syndrome.